Form 4: Evoke Pharma Director Reports Post-Merger Transactions

Evoke Pharma Director Cam L. Garner reports the disposition of common stock and cash conversion of stock options following the company's acquisition by QOL Medical, LLC.

Summary

• Evoke Pharma Inc. was acquired by QOL Medical, LLC and its wholly-owned subsidiary, QOL-EOS Merger Sub, Inc., through a tender offer.
• The tender offer was completed on December 16, 2025, with shareholders receiving $11.00 per share in cash for their common stock.
• The merger became effective on December 17, 2025, resulting in Evoke Pharma Inc. becoming a wholly-owned subsidiary of QOL Medical, LLC.
• Director Cam L. Garner reported the disposition of 2,330 shares of common stock, held indirectly by Garner Investments, L.L.C., on December 16, 2025, in connection with the tender offer.
• Stock options held by Cam L. Garner, with exercise prices of $5.41 (1,479 shares), $4.45 (8,750 shares), and $3.453 (1,291 shares), were accelerated, fully vested, canceled, and converted into cash payments on December 17, 2025, as per the merger agreement.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger and tender offer, providing a cash exit for shareholders and monetizing director stock options.

Positives

• Evoke Pharma Inc. common stockholders received $11.00 per share in cash as part of the tender offer, providing a clear exit value.
• Director Cam L. Garner's outstanding stock options were accelerated, fully vested, and converted into cash payments, indicating a successful monetization of these equity incentives.

Negatives

• Evoke Pharma Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of QOL Medical, LLC.

Future Outlook

The company has been acquired and is now a wholly-owned subsidiary, therefore, the filing does not provide forward-looking statements or guidance for its independent operations.

Industry Context

The acquisition of Evoke Pharma by QOL Medical reflects ongoing consolidation within the pharmaceutical sector, where smaller, specialized companies are often acquired for their product portfolios or intellectual property.

Stakeholder Impact

• Shareholders: Received $11.00 per share in cash for their common stock, ceasing to hold shares in a public entity.
• Director Cam L. Garner: Monetized beneficial ownership of common stock and stock options through the merger process.
• Employees: Evoke Pharma continues as the surviving corporation and a wholly-owned subsidiary, implying continuity of operations under new ownership.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Acquisition, Tender Offer, Form 4, Director Transactions, Stock Options, Beneficial Ownership